Karyopharm Therapeutics
KPTI
134 hedge funds and large institutions have $334M invested in Karyopharm Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 58 increasing their positions, 34 reducing their positions, and 33 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.17% less ownership
Funds ownership: 5.24% → 5.07% (-0.17%)
12% less funds holding
Funds holding: 153 → 134 (-19)
45% less capital invested
Capital invested by funds: $608M → $334M (-$273M)
58% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 33
72% less call options, than puts
Call options by funds: $2.28M | Put options by funds: $8.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$15.2M |
| 2 |
Renaissance Technologies
New York
|
+$3.3M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.18M |
| 4 |
Two Sigma Investments
New York
|
+$1.73M |
| 5 |
Morgan Stanley
New York
|
+$1.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$8.28M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$7.55M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$6.56M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.15M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$6.07M |
KPTI Hedge Fund Activity: Q3 2021 in Review
134 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2021, worth a combined $334M — down 45% from $608M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of KPTI and 14 opened new positions — a net loss of 19 holders — while 34 trimmed existing stakes and 58 added.
The largest buyer was State Street, adding an estimated $15.2M. The largest seller was Hood River Capital Management, exiting entirely with an estimated $8.28M sold.
- 134 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2021, down from 153 in Q2 2021.
- Funds reported $334M of Karyopharm Therapeutics stock for Q3 2021, down 45% quarter-over-quarter.
- 14 funds opened new Karyopharm Therapeutics positions in Q3 2021 and 33 closed out, a net change of -19 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2021 was State Street, an estimated $15.2M added.
- The largest Karyopharm Therapeutics seller in Q3 2021 was Hood River Capital Management, an estimated $8.28M sold.
Based on aggregated 13F filings for Q3 2021.